Valuation : Abivax

Market Cap 9.21B 10.68B 8.68B 7.91B 14.78B 1,009B 14.89B 103B 39.87B 516B 40.09B 39.22B 1,694B P/E 2026 *
-27.8x
P/E 2027 * -32.7x
Enterprise Value 8.11B 9.4B 7.64B 6.96B 13.01B 888B 13.11B 90.43B 35.1B 454B 35.29B 34.52B 1,491B EV / Sales 2026 *
108x
EV / Sales 2027 * 99.3x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-1.83%
1 week-3.74%
Current month-0.92%
1 month-9.93%
3 months+53.17%
6 months-2.96%
Current year-19.73%
1 week 95
Extreme 95
101.4
1 month 95
Extreme 95
115.8
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.9
Extreme 3.9
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
7/11/26 Exercice

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%-3.74%+40.07%+447.90% 10.68B
+0.97%-0.75%+3.51%+17.79% 49.74B
-1.05%-3.76%+424.54%+515.46% 44.98B
+1.69%+0.43%+42.94%+18.90% 42.52B
+0.81%-3.81%+8.87%+76.47% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+1.88%+5.47% - - 17.09B
+0.41%-5.48%+23.61%+120.71% 16.28B
+1.70%-0.05%+18.53%+28.09% 14.4B
+1.60%-3.15%+77.25%+39.91% 13.48B
Average +0.53%-2.56%+72.73%+145.96% 28.28B
Weighted average by Cap. +0.51%-2.31%+90.61%+140.27%

Financials

2026 *2027 *
Net sales 74.92M 86.85M 70.58M 64.31M 120M 8.2B 121M 836M 324M 4.19B 326M 319M 13.78B 82.73M 95.9M 77.94M 71.01M 133M 9.06B 134M 923M 358M 4.63B 360M 352M 15.22B
Net income -265M -307M -250M -228M -425M -29.03B -429M -2.96B -1.15B -14.84B -1.15B -1.13B -48.76B -231M -267M -217M -198M -370M -25.27B -373M -2.57B -999M -12.92B -1B -982M -42.43B
Net Debt -1.1B -1.28B -1.04B -946M -1.77B -121B -1.78B -12.3B -4.77B -61.72B -4.8B -4.69B -203B -993M -1.15B -935M -852M -1.59B -109B -1.6B -11.07B -4.3B -55.57B -4.32B -4.23B -183B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-09-02 96.65 -1.83% 106,964
26-09-01 €98.45 +0.92% 167,955
26-08-31 €97.55 +0.15% 926,854
26-08-28 €97.40 -2.55% 127,732
26-08-27 €99.95 -0.45% 85,504
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
98.45EUR
Average target price
138.97EUR
Spread / Average Target
+41.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock